EBR Systems Wins TGA Priority Review for WiSE Wireless CRT in Australia

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has provided an update.

EBR Systems has secured a Priority Review Determination from Australia’s Therapeutic Goods Administration for its WiSE wireless cardiac resynchronisation therapy system, an expedited pathway that could shorten regulatory evaluation from 225 to about 150 working days. The move follows U.S. FDA approval in 2025 and supports faster Australian market entry, complementing early U.S. commercial rollout.

The company plans to file for inclusion of WiSE on the Australian Register of Therapeutic Goods, which would enable earlier access to a leadless pacing option for heart failure patients who have limited or unsuccessful experience with conventional CRT. The Priority Review adds to growing regulatory, commercial and clinical momentum for EBR Systems, potentially strengthening its competitive position in advanced cardiac pacing and expanding treatment options for patients with high unmet need.

The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.43 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

EBR Systems, Inc. is a Silicon Valley-based medical device company focused on treating cardiac rhythm disease through wireless cardiac pacing technology. Its proprietary Wireless Stimulation Endocardially (WiSE) platform eliminates traditional pacing leads, initially targeting heart failure patients needing cardiac resynchronisation therapy who cannot benefit from conventional lead-based systems, with future applications anticipated in bradycardia and other indications.

Average Trading Volume: 551,194

Technical Sentiment Signal: Sell

Current Market Cap: A$2.93B

For a thorough assessment of EBR stock, go to TipRanks’ Stock Analysis page.